Cendakimab
申达奇单抗
Report date: 2026/05/26 20:00:28
Base Information
Drug NameCendakimab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[5]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[17]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbbott Laboratories
China Registration ClassN/A
Develop Information
Active CompaniesCelgene International Ii SarlBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co Ltd +[7]
Inactive CompaniesAbbvie Inc
Active Indications +[4]
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A